Pyxis Oncology (NASDAQ:PYXS) Stock Rating Raised to "Outperform" at William Blair

Pyxis Oncology logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • William Blair upgraded Pyxis Oncology to “outperform” from “market perform.”
  • Analyst sentiment is broadly positive: eight analysts rate the stock Buy and one Sell, with a consensus “Moderate Buy” rating and an $8.71 price target.
  • PYXS opened at $1.68, versus a 12-month range of $1.03–$5.55. The company reported quarterly EPS of -$0.24, beating the -$0.27 consensus estimate.
  • Five stocks to consider instead of Pyxis Oncology.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) was upgraded by equities research analysts at William Blair from a "market perform" rating to an "outperform" rating in a report released on Friday, MarketBeat.com reports.

Several other research firms also recently issued reports on PYXS. Wedbush dropped their target price on Pyxis Oncology from $8.00 to $7.00 and set an "outperform" rating on the stock in a research report on Friday, November 6th. Royal Bank Of Canada lifted their price target on Pyxis Oncology from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, November 6th. HC Wainwright boosted their price objective on Pyxis Oncology from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Thursday, September 10th. Stifel Nicolaus set a $5.00 price objective on Pyxis Oncology in a report on Thursday, November 5th. Finally, Weiss Ratings upgraded Pyxis Oncology from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $8.71.

Read Our Latest Report on Pyxis Oncology

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $1.68 on Friday. The company's 50 day moving average is $2.16 and its 200-day moving average is $2.15. Pyxis Oncology has a 12-month low of $1.03 and a 12-month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, equities analysts expect that Pyxis Oncology will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its holdings in shares of Pyxis Oncology by 221.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 147,598 shares of the company's stock valued at $344,000 after acquiring an additional 101,698 shares in the last quarter. Jump Financial LLC purchased a new position in shares of Pyxis Oncology during the third quarter worth about $150,000. Empowered Funds LLC purchased a new position in shares of Pyxis Oncology during the third quarter worth about $219,000. Blue Owl Capital Holdings LP purchased a new position in shares of Pyxis Oncology during the third quarter worth about $2,330,000. Finally, Commonwealth Equity Services LLC increased its position in shares of Pyxis Oncology by 14.8% in the third quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company's stock worth $114,000 after purchasing an additional 6,295 shares during the last quarter. 39.07% of the stock is currently owned by hedge funds and other institutional investors.

About Pyxis Oncology

(Get Free Report)

Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company's pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology's broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.

Further Reading

Analyst Recommendations for Pyxis Oncology (NASDAQ:PYXS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pyxis Oncology Right Now?

Before you consider Pyxis Oncology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.

While Pyxis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines